MedPath

Takeda Pharmaceutical Company Ltd

🇸🇪Sweden
Ownership
-
Established
1925-01-01
Employees
-
Market Cap
$47.5B
Website
http://www.takeda.co.jp/

Central Nervous System (CNS) Therapeutics Market Forecast

The global central nervous system therapeutics market, valued at USD 144.3M in 2024, is projected to reach USD 431M by 2035, growing at a CAGR of 10.46%. Growth drivers include rising neurological disorders, advancements in drug development, and increased R&D investments. Key segments include mental health and neurodegenerative diseases, with CNS stimulants and anticonvulsants leading in drug class. North America leads in revenue, while Asia Pacific is the fastest-growing region.
biospace.com
·

Layoff Tracker: Cassava Axes Third of Staff in Aftermath of Failed Phase III Alzheimer's Drug Trial

2024 was a challenging year for the biopharma industry, with companies like Bayer, Bristol Myers Squibb, and Johnson & Johnson cutting hundreds to thousands of jobs. Cassava Sciences announced layoffs of 10 employees, 33% of its workforce, following a failed Phase III trial for its Alzheimer's drug. CytomX Therapeutics cut 40% of its staff to focus on clinical programs. Velia, a San Diego biotech, is shutting down, affecting 47 employees. Regeneron's acquisition of Oxular led to layoffs, with no Oxular employees joining Regeneron. Javara, Ring Therapeutics, Outlook Therapeutics, Editas, Bavarian Nordic, BenevolentAI, Chroma Medicine and Nvelop Therapeutics, Cellectar Biosciences, Carisma Therapeutics, Belharra Therapeutics, National Resilience, AmplifyBio, Agenus, Alligator Bioscience, Idorsia Pharmaceuticals, Kronos Bio, Novartis, Recursion Therapeutics, Medigene, Alector, Bristol Myers Squibb, Sonata Therapeutics, 23andMe, Johnson & Johnson, Merck, Gilead Sciences, Adaptimmune, Sensei Biotherapeutics, Marinus Pharmaceuticals, Orna Therapeutics, Thermo Fisher Scientific, Charles River Laboratories, Aurinia Pharmaceuticals, Viracta Therapeutics, Astellas Gene Therapies, Sana Biotechnology, Sage Therapeutics, Compass Pathways, Spero Therapeutics, ICON, Pfizer, Takeda, SalioGen Therapeutics, Evonik, Medtronic, CareFusion Resources, Turnstone Biologics, Leo Pharma, Astellas Pharma, Prime Medicine, Kaléo, Stryker, Relay Therapeutics, ImmunityBio, Shattuck Labs, Inventprise, bluebird bio, Athira Pharma, AGC Biologics, Oncternal Therapeutics, Biosense Webster, Vesigen Therapeutics, Connect Biopharma, BioMarin, IN8bio, Edwards Lifesciences, DermTech, Repare Therapeutics, Genentech, Tome Biosciences, Aadi Bioscience, Lykos Therapeutics, Evotec, Galera Therapeutics, Grail, Ovid Therapeutics, Lexicon Pharmaceuticals, Acelyrin, Boundless Bio, FibroGen, Ajinomoto Bio-Pharma Services, AN2 Therapeutics, Entero Therapeutics, Precigen, Sumitomo Pharma America, uniQure, Vir Biotechnology, Arbutus Biopharma, HilleVax, and Bayer also announced significant layoffs, reflecting a tough year for the industry.
ddw-online.com
·

Narcolepsy Acquisitions to Boost Neuraxpharm's CNS Reach

Neuraxpharm acquired Provigil and Nuvigil, treatments for Excessive Daytime Sleepiness in narcolepsy, expanding its CNS disorder portfolio. This move aligns with its strategy to grow CNS brands globally, entering new markets like Australia and strengthening presence in Mexico, following previous acquisitions and partnerships.
drugstorenews.com
·

ANI Launches Generic Motegrity

ANI introduces prucalopride tablets, the generic version of Takeda's Motegrity, for treating chronic idiopathic constipation in adults. With FDA's Competitive Generic Therapy designation and 180-day exclusivity, ANI highlights its R&D strength. The market value was about $168 million as of October 2024.
finance.yahoo.com
·

Neuraxpharm to further grow branded business with the acquisition of Provigil and Nuvigil

Neuraxpharm acquired Provigil® (modafinil) and Nuvigil® (armodafinil), enhancing its CNS treatment portfolio and expanding into new markets like Australia. These drugs treat narcolepsy's Excessive Daytime Sleepiness, marking Neuraxpharm's strategic growth in CNS disorders globally.
prnewswire.com
·

Neuraxpharm to further grow branded business with the acquisition of Provigil® and Nuvigil®

Neuraxpharm Group acquired Provigil® and Nuvigil®, enhancing its CNS portfolio and expanding into new markets like Australia. These drugs treat narcolepsy's Excessive Daytime Sleepiness. The move aligns with Neuraxpharm's strategy to grow CNS brands globally, following previous acquisitions and partnerships.
pharmaphorum.com
·

Lundbeck and Takeda seek FDA approval for antidepressant drug

Takeda Pharmaceuticals and Lundbeck submitted an NDA to the US FDA for vortioxetine, an investigational antidepressant for MDD. Supported by global trials involving 7,500 participants, vortioxetine shows efficacy in a 5-20mg dose range. MDD affects 121 million globally, highlighting the need for new treatments.
pharmaphorum.com
·

J&J gets CHMP nod for Rybrevant in first-line lung cancer

Johnson & Johnson’s Rybrevant nears EU approval for EGFR-positive lung cancer treatment, following EMA’s CHMP recommendation. Proven effective in the PAPILLON study, it significantly reduces disease progression risk. J&J aims to expand Rybrevant’s use, challenging AstraZeneca’s Tagrisso, amidst emerging competitors in the NSCLC treatment landscape.
pharmaphorum.com
·

ASH: Sanofi’s Sarclisa carves out a multiple myeloma niche

Sanofi's Sarclisa showed improved MRD negativity rates in multiple myeloma patients when added to KRd regimen, as per IsKia trial data. Despite lagging behind Darzalex in sales, new trial results could boost Sarclisa's market position. Sarclisa is also under phase 3 trial for a new combination therapy.
© Copyright 2025. All Rights Reserved by MedPath